This article was originally published in The Tan Sheet
Former FDA Chief Counsel Dan Troy and Special Assistant to the Chief Counsel Coleen Klasmeier will join Sidley Austin Brown & Wood this month, the law firm announces Jan. 6. Troy will provide "strategic counsel on FDA-related matters" and practice administrative and constitutional law with a focus on the pharma, biotech and medical device industries; he announced his departure from FDA in November (1"The Tan Sheet" Nov. 22, 2004, p. 10). Klasmeier is joining the firm's life sciences practice with a focus on the pharma, medical device and food industries...
You may also be interested in...
The FDA Office of Chief Counsel's review of warning and untitled letters has resulted in the rejection of approximately 5% of letters, outgoing Chief Counsel Daniel Troy said
A WHO recommendation to explicitly exempt low-THC CBD from international narcotics controls has been emphatically rejected by UN member states. The CBD industry had hoped for a positive outcome to remove regulatory pressure on product manufacturers in Europe and around the world.
After its historic first emergency approval, analysts at Bernstein has upgraded predictions for Pfizer/BioNTech's COVID-19 vaccine in 2021 and beyond.